drugset / Trial / NCT00302653

Rasburicase in Tumor Lysis Syndrome

NCT00302653

Phase 4 Completed 33 enrolled Sanofi
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether rasburicase is effective and safety in correcting hyperuricemia.

Timeline

Start
2006-02
Primary completion
2006-11
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Rasburicase Protein / enzyme biologic 0.2 mg/kg

Indications

No indication recorded.